

## Product datasheet for **SR319563**

### Caspase 8 (CASP8) Human siRNA Oligo Duplex (Locus ID 841)

#### Product data:

|                     |   |
|---------------------|---|
| Product Type:       | siRNA Oligo Duplexes  |
| Purity:             | HPLC purified   |
| Quality Control:    | Tested by ESI-MS  |
| Sequences:          | Available with shipment   |
| Stability:          | One year from date of shipment when stored at -20°C.  |
| # of transfections: | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).  |
| Note:               | Single siRNA duplex (10nmol) can be ordered.  |
| RefSeq:             | <a href="#">NM_001080124</a> , <a href="#">NM_001080125</a> , <a href="#">NM_001228</a> , <a href="#">NM_033355</a> , <a href="#">NM_033356</a> , <a href="#">NM_033357</a> ,<br><a href="#">NM_033358</a> , <a href="#">NR_111983</a>  |
| UniProt ID:         | <a href="#">Q14790</a>  |
| Synonyms:           | ALPS2B; CAP4; Casp-8; FLICE; MACH; MCH5   |
| Components:         | CASP8 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 841)<br>Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol<br>Included - SR30005, RNase free siRNA Duplex Resuspension Buffer - 2 ml   |
| Summary:            | This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alternatively spliced transcript variants encoding different isoforms have been described, although not all variants have had their full-length sequences determined. [provided by RefSeq, Jul 2008] |



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).